{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:11:14Z","timestamp":1786990274843,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":177,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.idcr.2020.e00892","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T14:18:38Z","timestamp":1593181118000},"page":"e00892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Necessity to screen and treat latent tuberculosis before ruxolitinib treatment\u2014Ruxolitinib-associated disseminated tuberculosis: A case report and literature review"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-7340","authenticated-orcid":false,"given":"Nobuyasu","family":"Hirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-5528","authenticated-orcid":false,"given":"Tomoko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-8199","authenticated-orcid":false,"given":"Naokuni","family":"Hishiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakazu","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Mikasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2020.e00892_bib0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2020.e00892_bib0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.idcr.2020.e00892_bib0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.idcr.2020.e00892_bib0020","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.idcr.2020.e00892_bib0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-016-2684-0","article-title":"Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib","volume":"95","author":"Branco","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.idcr.2020.e00892_bib0030","article-title":"Ruxolitinib associated tuberculosis presenting as a neck lump","volume":"2015","author":"Shamil","year":"2015","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.idcr.2020.e00892_bib0035","first-page":"A8650","article-title":"Fatal tuberculosis during treatment with ruxolitinib","volume":"159","author":"Keizer","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.idcr.2020.e00892_bib0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2169\/internalmedicine.9165-17","article-title":"Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: a case report and review of the literature","volume":"57","author":"Tsukamoto","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.idcr.2020.e00892_bib0045","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","article-title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.idcr.2020.e00892_bib0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","article-title":"Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge","volume":"94","author":"Palandri","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.idcr.2020.e00892_bib0055","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/leu.2014.104","article-title":"Disseminated tuberculosis associated with ruxolitinib","volume":"28","author":"Hopman","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.idcr.2020.e00892_bib0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.idcr.2020.e00892_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217854","article-title":"Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2 years follow-up","volume":"2016","author":"Panda","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.idcr.2020.e00892_bib0070","article-title":"Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib","volume":"2016","author":"Abidi","year":"2016","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.idcr.2020.e00892_bib0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijid.2019.01.002","article-title":"Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera","volume":"80","author":"Lescuyer","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.idcr.2020.e00892_bib0080","first-page":"201","article-title":"Trends in tuberculosis--United States, 2012","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.idcr.2020.e00892_bib0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idcr.2020.e00892_bib0090","first-page":"1","article-title":"Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.idcr.2020.e00892_bib0095","first-page":"881","article-title":"The issue of tuberculosis in the elderly in Japan","volume":"85","author":"Toyota","year":"2010","journal-title":"Kekkaku"},{"key":"10.1016\/j.idcr.2020.e00892_bib0100","first-page":"S221","article-title":"CDC targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.idcr.2020.e00892_bib0105","first-page":"1021","article-title":"Waning of the specific interferon-gamma response after years of tuberculosis infection","volume":"11","author":"Mori","year":"2007","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250920302006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250920302006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:04:46Z","timestamp":1761998686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250920302006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":21,"alternative-id":["S2214250920302006"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2020.e00892","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Necessity to screen and treat latent tuberculosis before ruxolitinib treatment\u2014Ruxolitinib-associated disseminated tuberculosis: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2020.e00892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e00892"}}